Oxford BioDynamics has completed a test development using the EpiSwitch technology, to differentiate the least aggressive cases of prostate cancer from those that are more aggressive. Least aggressive tumours are categorized as Gleason score 4-6 and either Stage I/II or from patients older than 65, whilst more aggressive cases are Gleason grade 7 and above, and either Stage III+ or less than 65 years old. The test can accurately identify the two groups, providing essential information for physicians to determine whether patients require observation or intervention.